ArticleCureus2026
Efficacy of Automated Red Cell Exchange for Sickle Cell Disease: A Cross-Sectional Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSickle cell disease is a hereditary hemoglobinopathy commonly seen in sub-Saharan Africa, India, and the Middle East. It is caused by a mutation in the β-globin gene and is associated with both acute and chronic multiorgan complications, including severe anemia and stroke. Materials and methods: This cross-sectional study was carried out over a period of one year (2022-2023) among patients with sickle cell disease. Automated red cell exchange was performed using a continuous-flow cell separator to assess the procedural efficiency.
resultsA total of 30 male and female patients with sickle cell disease from districts surrounding Indore were included. The mean age was 23.4 years, and procedures were performed for various indications as per the American Society for Apheresis (ASFA) guidelines. Most cases, 27 (90%), fell under category II. Thirty automated red cell exchange procedures were performed. Among these, 17 (57%) patients achieved a hemoglobin S (HbS) reduction of 71-80%, eight (27%) >81% reduction, four (13%) 61-70% reduction, and one (3%) <60% reduction.
conclusionAutomated red cell exchange led to significant improvement in multiple hematological parameters, including hemoglobin levels, hematocrit, indirect bilirubin, and HbS percentage, supporting its effectiveness in the management of sickle cell disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.